Mark L. Ratner
There’s been an upswing in interest in diagnostics by some of the more influential VCs and once again it’s triggering talk of whether—and in what areas—genomics- or proteomics-based tests could form the basis for a sustainable business. (See "Pharma Venturing in Diagnostics," sidebar in "Wake-up Calls in IVD," IN VIVO, April 2007 Also see "Wake-up Calls in IVD" - In Vivo, 1 April, 2007.